StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL – Free Report) in a report issued on Tuesday morning. The firm issued a sell rating on the medical technology company’s stock.
A number of other research analysts also recently commented on BIOL. Ascendiant Capital Markets lowered their price objective on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Benchmark restated a “speculative buy” rating and set a $0.40 price objective on shares of BIOLASE in a research note on Wednesday, October 2nd.
Get Our Latest Stock Report on BIOLASE
BIOLASE Price Performance
Institutional Inflows and Outflows
An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC increased its position in BIOLASE, Inc. (NASDAQ:BIOL – Free Report) by 1,068.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. 8.79% of the stock is owned by hedge funds and other institutional investors.
BIOLASE Company Profile
BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.
Read More
- Five stocks we like better than BIOLASE
- What is Short Interest? How to Use It
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Top-Performing Non-Leveraged ETFs This Year
- Basic Materials Stocks Investing
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for BIOLASE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIOLASE and related companies with MarketBeat.com's FREE daily email newsletter.
